HomeBUSINESS
BUSINESS

Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
(Nov.1.2017)

Daiichi Sankyo managed to secure a 2.5% rise in its half-year group sales despite the patent expiry of Olmetec (olmesartan), the company’s top-selling product, as it was helped by strong growth of the anticoagulant Lixiana (edoxaban) and other mainstay products ...
(LOG IN FOR FULL STORY)

News Calendar